Arena Pharma Raising $352 Million Following Positive Phase II Data

Arena Pharmaceuticals is hoping to raise $352 million from a stock offering just days after releasing positive top-line results from its Phase II trial of etrasimod in ulcerative colitis.
Source: BioSpace